Shilu Luo

960 total citations · 1 hit paper
36 papers, 620 citations indexed

About

Shilu Luo is a scholar working on Molecular Biology, Epidemiology and Cell Biology. According to data from OpenAlex, Shilu Luo has authored 36 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 12 papers in Epidemiology and 12 papers in Cell Biology. Recurrent topics in Shilu Luo's work include Endoplasmic Reticulum Stress and Disease (8 papers), Autophagy in Disease and Therapy (7 papers) and Mitochondrial Function and Pathology (6 papers). Shilu Luo is often cited by papers focused on Endoplasmic Reticulum Stress and Disease (8 papers), Autophagy in Disease and Therapy (7 papers) and Mitochondrial Function and Pathology (6 papers). Shilu Luo collaborates with scholars based in China. Shilu Luo's co-authors include Ming Yang, Lin Sun, Na Jiang, Chongbin Liu, Chenrui Li, Jinfei Yang, Yachun Han, Kaiyue Ding, Li Li and Hao Zhao and has published in prestigious journals such as Diabetes, Journal of Agricultural and Food Chemistry and Frontiers in Immunology.

In The Last Decade

Shilu Luo

35 papers receiving 616 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism

2023 153 citations Chongbin Liu, Ming Yang et al. profile →

Peers

Shilu Luo

MB

PRM

EPIDE

CB

PHYSI

Zijing Zhu China

Lihua Li China

Jinfei Yang China

Xinxu Yuan United States

Sivakama S. Bharathi United States

Shiqun Sun China

Mason Breitzig United States

Jinzhao He China

Audrey Swiader France

Jiamei Lu China

Zijing Zhu China

Shilu Luo

402 ×1.3

MB

52 ×0.4

PRM

114 ×0.9

EPIDE

57 ×0.5

CB

72 ×0.7

PHYSI

Citations per year, relative to Shilu Luo Shilu Luo (= 1×) peers Zijing Zhu

Countries citing papers authored by Shilu Luo

Since Specialization

Citations

This map shows the geographic impact of Shilu Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shilu Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shilu Luo more than expected).

Fields of papers citing papers by Shilu Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shilu Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shilu Luo. The network helps show where Shilu Luo may publish in the future.

Co-authorship network of co-authors of Shilu Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Shilu Luo. A scholar is included among the top collaborators of Shilu Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shilu Luo. Shilu Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Luo, Shilu, et al.. (2025). CAV1 Exacerbates Renal Tubular Epithelial Cell Senescence by Suppressing CaMKK2/AMPK‐Mediated Autophagy. Aging Cell. 24(5). e14501–e14501.

2.

Yang, Ming, Chongbin Liu, Na Jiang, et al.. (2025). Sesamol Ameliorates Lipid Deposition by Maintaining the Integrity of the Lipid Droplet–Mitochondria Connection in Diabetic Nephropathy. Journal of Agricultural and Food Chemistry. 73(3). 2124–2137. 2 indexed citations

3.

Yang, Ming, Yan Liu, Shilu Luo, et al.. (2024). DsbA-L ameliorates renal aging and renal fibrosis by maintaining mitochondrial homeostasis. Acta Pharmacologica Sinica. 45(4). 777–789. 10 indexed citations

4.

Yang, Jinfei, Li Li, Chenrui Li, et al.. (2023). PACS-2 deficiency aggravates tubular injury in diabetic kidney disease by inhibiting ER-phagy. Cell Death and Disease. 14(10). 649–649. 9 indexed citations

5.

Yang, Ming, Chongbin Liu, Na Jiang, et al.. (2023). Fibroblast growth factor 21 in metabolic syndrome. Frontiers in Endocrinology. 14. 1220426–1220426. 18 indexed citations

6.

Yang, Ming, Chongbin Liu, Na Jiang, et al.. (2023). Mitochondrial homeostasis: a potential target for delaying renal aging. Frontiers in Pharmacology. 14. 1191517–1191517. 5 indexed citations

7.

Liu, Yan, Chenrui Li, Li Li, et al.. (2023). DsbA-L interacting with catalase in peroxisome improves tubular oxidative damage in diabetic nephropathy. Redox Biology. 66. 102855–102855. 15 indexed citations

8.

Yang, Ming, Chongbin Liu, Na Jiang, et al.. (2023). Myostatin: a potential therapeutic target for metabolic syndrome. Frontiers in Endocrinology. 14. 1181913–1181913. 16 indexed citations

9.

Yang, Ming, Chongbin Liu, Na Jiang, et al.. (2023). Endoplasmic reticulum homeostasis: a potential target for diabetic nephropathy. Frontiers in Endocrinology. 14. 1182848–1182848. 12 indexed citations

10.

Yang, Ming, Shilu Luo, Jinfei Yang, et al.. (2022). Myokines: Novel therapeutic targets for diabetic nephropathy. Frontiers in Endocrinology. 13. 1014581–1014581. 11 indexed citations

11.

Liu, Chongbin, Ming Yang, Li Li, et al.. (2022). A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease. Frontiers in Physiology. 13. 909569–909569. 11 indexed citations

12.

Yang, Ming, Shilu Luo, Jinfei Yang, et al.. (2022). Lipid droplet - mitochondria coupling: A novel lipid metabolism regulatory hub in diabetic nephropathy. Frontiers in Endocrinology. 13. 1017387–1017387. 25 indexed citations

13.

Yang, Jinfei, Chenrui Li, Yan Liu, et al.. (2022). Using network pharmacology to explore the mechanism of Danggui-Shaoyao-San in the treatment of diabetic kidney disease. Frontiers in Pharmacology. 13. 832299–832299. 7 indexed citations

14.

Yang, Ming, Shilu Luo, Jinfei Yang, et al.. (2022). Crosstalk between the liver and kidney in diabetic nephropathy. European Journal of Pharmacology. 931. 175219–175219. 6 indexed citations

15.

Li, Li, Chenrui Li, Chengyuan Tang, et al.. (2022). PACS-2 deficiency in tubular cells aggravates lipid-related kidney injury in diabetic kidney disease. Molecular Medicine. 28(1). 117–117. 20 indexed citations

16.

Luo, Shilu, Jinfei Yang, Wei Chen, et al.. (2022). Bone-kidney axis: A potential therapeutic target for diabetic nephropathy. Frontiers in Endocrinology. 13. 996776–996776. 6 indexed citations

17.

Luo, Shilu, Ming Yang, Hao Zhao, et al.. (2022). Mitochondrial DNA-dependent inflammation in kidney diseases. International Immunopharmacology. 107. 108637–108637. 5 indexed citations

18.

Yang, Ming, Shilu Luo, Na Jiang, et al.. (2021). DsbA-L Ameliorates Renal Injury Through the AMPK/NLRP3 Inflammasome Signaling Pathway in Diabetic Nephropathy. Frontiers in Physiology. 12. 659751–659751. 26 indexed citations

19.

Luo, Shilu, Ming Yang, Hao Zhao, et al.. (2021). Caveolin-1 Regulates Cellular Metabolism: A Potential Therapeutic Target in Kidney Disease. Frontiers in Pharmacology. 12. 768100–768100. 24 indexed citations

20.

Huang, Jian, Shilu Luo, Meirong Huang, et al.. (2019). Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein. Microbial Pathogenesis. 129. 206–212. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact